Georg Schett

Summary

Affiliation: University of Erlangen-Nuremberg
Country: Germany

Publications

  1. ncbi A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis
    Stephanie Finzel
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 70:122-7. 2011
  2. ncbi [Clinical symptoms and pathophysiology of osteophyte formation and ankylosis]
    G Schett
    Medizinische Klinik 3, Rheumatologie and Immunologie, Universitatsklinikum Erlangen, Krankenhausstr 12, 91054, Erlangen, Deutschland
    Z Rheumatol 71:217-9. 2012
  3. ncbi Risk of infections in rheumatoid arthritis patients treated with tocilizumab
    Veronika R Lang
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Krankenhausstrasse 12, 91054 Erlangen, Germany
    Rheumatology (Oxford) 51:852-7. 2012
  4. ncbi High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis
    Gisela Ruiz Heiland
    Department of Internal Medicine III, University of Erlangen Nuremberg, Germany
    Ann Rheum Dis 71:572-4. 2012
  5. ncbi Effects of inflammatory and anti-inflammatory cytokines on the bone
    Georg Schett
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Erlangen, Germany
    Eur J Clin Invest 41:1361-6. 2011
  6. ncbi [Osteoimmunology - IMMUNOBONE - Understanding the interaction between bone and immune system]
    G Schett
    Medizinische Klinik 3, Rheumatologie and Immunologie, Friedrich Alexander Universitat Erlangen Nurnberg, Universitatsklinikum Erlangen, Erlangen, Deutschland
    Z Rheumatol 71:138-9. 2012
  7. ncbi Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities
    Morten A Karsdal
    Nordic Bioscience, Herlev Hovedgade 207, DK 2730 Herlev, Denmark
    Arthritis Res Ther 13:215. 2011
  8. ncbi RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies
    Marina Stolina
    Department of Metabolic Disorders, Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, USA
    Arthritis Res Ther 11:R187. 2009
  9. ncbi Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis
    Christian Beyer
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Res Ther 11:220. 2009
  10. ncbi Osteoimmunology in rheumatic diseases
    Georg Schett
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Res Ther 11:210. 2009

Detail Information

Publications156 found, 100 shown here

  1. ncbi A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis
    Stephanie Finzel
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 70:122-7. 2011
    ..Psoriatic arthritis (PsA) and rheumatoid arthritis (RA) are both destructive arthritides but may differ substantially in their periarticular bone changes...
  2. ncbi [Clinical symptoms and pathophysiology of osteophyte formation and ankylosis]
    G Schett
    Medizinische Klinik 3, Rheumatologie and Immunologie, Universitatsklinikum Erlangen, Krankenhausstr 12, 91054, Erlangen, Deutschland
    Z Rheumatol 71:217-9. 2012
    ..It could be shown that low levels of Dickkopf-1 protein, which is stimulated by TNF-?, promote the formation of bone spurs...
  3. ncbi Risk of infections in rheumatoid arthritis patients treated with tocilizumab
    Veronika R Lang
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Krankenhausstrasse 12, 91054 Erlangen, Germany
    Rheumatology (Oxford) 51:852-7. 2012
    ..e. previous exposure to rituximab and those receiving concomitant LEF, prednisone or proton-pump inhibitor treatment...
  4. ncbi High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis
    Gisela Ruiz Heiland
    Department of Internal Medicine III, University of Erlangen Nuremberg, Germany
    Ann Rheum Dis 71:572-4. 2012
    ..The molecular mechanisms of syndesmophyte formation in ankylosing spondylitis (AS) are yet to be characterised. Molecules involved in bone formation such as Wnt proteins and their antagonists probably drive syndesmophyte formation in AS...
  5. ncbi Effects of inflammatory and anti-inflammatory cytokines on the bone
    Georg Schett
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Erlangen, Germany
    Eur J Clin Invest 41:1361-6. 2011
    ..Inflammatory diseases are linked to enhanced bone loss. The effect of inflammation on bone is mediated by proinflammatory cytokines, which regulate bone formation as well as bone resorption thereby altering bone homeostasis...
  6. ncbi [Osteoimmunology - IMMUNOBONE - Understanding the interaction between bone and immune system]
    G Schett
    Medizinische Klinik 3, Rheumatologie and Immunologie, Friedrich Alexander Universitat Erlangen Nurnberg, Universitatsklinikum Erlangen, Erlangen, Deutschland
    Z Rheumatol 71:138-9. 2012
    ..The molecular mechanisms involved in bone damage and the interaction between the immune system and bone and cartilage are topics of research...
  7. ncbi Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities
    Morten A Karsdal
    Nordic Bioscience, Herlev Hovedgade 207, DK 2730 Herlev, Denmark
    Arthritis Res Ther 13:215. 2011
    ....
  8. ncbi RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies
    Marina Stolina
    Department of Metabolic Disorders, Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, USA
    Arthritis Res Ther 11:R187. 2009
    ..RANKL inhibition consistently prevents bone loss in both models without reducing joint inflammation. Effects of these therapies on systemic markers of bone turnover and inflammation have not been directly compared...
  9. ncbi Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis
    Christian Beyer
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Res Ther 11:220. 2009
    ..Altogether, hypoxia might play a central role in pathogenesis of SSc by augmenting vascular disease and tissue fibrosis...
  10. ncbi Osteoimmunology in rheumatic diseases
    Georg Schett
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Res Ther 11:210. 2009
    ..This review highlights the key insights into the regulation of bone destruction and formation in arthritis. Moreover, concepts of how bone influences the immune system are discussed...
  11. ncbi [Early rheumatoid arthritis]
    G Schett
    Universitätsklinik für Innere Medizin 3, Universitat Erlangen Nurnberg, Postfach 2306, 91012, Erlangen
    Internist (Berl) 49:263-70. 2008
    ..Therefore, an effective approach to treat RA as early as possible warrants a detailed knowledge of the specific features of early RA, which not always follows the features of the established disease...
  12. ncbi Can we stop progression of ankylosing spondylitis?
    Georg Schett
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Krankenhausstrasse 12, D 91054 Erlangen, Germany
    Best Pract Res Clin Rheumatol 24:363-71. 2010
    ..The article reviews the current knowledge regarding the mechanisms and clinical role of ankylosis and explains strategies on how to prevent it in patients with ankylosing spondylitis...
  13. ncbi The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis
    G Schett
    Department of Internal Medicine III, University of Erlangen, D 91054 Erlangen, Germany
    Ann Rheum Dis 67:909-16. 2008
    ..It gives an overview of current evidence of p38MAPK activation in inflammatory arthritis and elaborates the key molecular determinants which contribute to p38MAPK activation in joint disease...
  14. ncbi Mr Outside and Mr Inside: classic and alternative views on the pathogenesis of rheumatoid arthritis
    Georg Schett
    University of Erlangen, Erlangen D 91054, Germany
    Ann Rheum Dis 69:787-9. 2010
    ..The authors discuss these two fundamentally different viewpoints on the pathogenesis of arthritis, each one of which bears attractive explanations for the mystery of the pathogenesis of arthritis...
  15. ncbi Inflammation and repair mechanisms
    G Schett
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Erlangen, Germany
    Clin Exp Rheumatol 27:S33-5. 2009
    ..It can be expected that the rapidly expanding new field of osteoimmunology will help to clarify the pathogenesis of the these two diseases with possible implications for new treatment targets...
  16. ncbi Bone formation versus bone resorption in ankylosing spondylitis
    Georg Schett
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Erlangen, Germany
    Adv Exp Med Biol 649:114-21. 2009
    ..AS may thus be considered as a synthesis of inflammatory disease and bone disease...
  17. ncbi Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis
    Georg Schett
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Krankenhausstrasse 12, Erlangen, Germany
    Arthritis Rheum 60:2644-54. 2009
    ....
  18. ncbi Vascular cell adhesion molecule 1 as a predictor of severe osteoarthritis of the hip and knee joints
    Georg Schett
    Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 60:2381-9. 2009
    ..Osteoarthritis (OA) is a leading cause of pain and physical disability in middle-aged and older individuals. We undertook this study to determine predictors of the development of severe OA, apart from age and overweight...
  19. ncbi The role of Wnt proteins in arthritis
    Georg Schett
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Erlangen, Germany
    Nat Clin Pract Rheumatol 4:473-80. 2008
    ..It also addresses the role of Wnt in determining the differences in clinical presentation of inflammatory arthropathies and discusses implications for future therapy...
  20. ncbi Bone marrow edema
    Georg Schett
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Krankenhausstrasse 12, Erlangen, Germany
    Ann N Y Acad Sci 1154:35-40. 2009
    ..However, even without erosive change, periarticular bone marrow lesions may be seen. This chapter describes the nature of bone marrow lesions detected by MRI in patients with inflammatory arthritis...
  21. ncbi Structural bone changes in spondyloarthritis: mechanisms, clinical impact and therapeutic considerations
    Georg Schett
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Am J Med Sci 341:269-71. 2011
    ..In this article, the authors discuss the pathophysiology of structural damage in SpA and concepts for the preservation of the physiologic bone architecture in patients with SpA...
  22. ncbi Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future
    Georg Schett
    Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen Nuremberg, Krankenhausstrasse 12, 91054 Erlangen, Germany
    Arthritis Res Ther 13:S4. 2011
    ....
  23. ncbi Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis
    Alfiya Akhmetshina
    Department of Internal Medicine III, University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 60:219-24. 2009
    ....
  24. ncbi Regulatory T cells protect from local and systemic bone destruction in arthritis
    Mario M Zaiss
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Erlangen, Germany
    J Immunol 184:7238-46. 2010
    ..Thus, enhancing the activity of Treg cells would be beneficial for the treatment of inflammation-induced bone loss observed in rheumatoid arthritis...
  25. ncbi Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis
    Clara Dees
    Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen Nuremberg, Germany
    Ann Rheum Dis 70:1304-10. 2011
    ..Dermal fibroblasts from patients with systemic sclerosis (SSc) release excessive amounts of collagen resulting in tissue fibrosis. The molecular mechanisms underlying this pathological activation are incompletely understood...
  26. ncbi Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo
    Paulius Venalis
    Department for Internal Medicine 3 and Institute for Clinical Immunology, Friedrich Alexander University Erlangen Nuremberg, Erlangen, Germany
    J Cell Mol Med 13:4185-91. 2009
    ..Imatinib does not inhibit activation, viability, proliferation, migration or tube forming of endothelial cells in vitro and in vivo. Thus, treatment with imatinib might not augment further endothelial cell damage in SSc...
  27. ncbi The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis
    Nicole Reich
    University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 62:280-90. 2010
    ..The aim of the present study was to investigate whether Fra-2 plays a role in the pathogenesis of SSc and to identify the molecular mechanisms by which Fra-2 induces fibrosis...
  28. ncbi R-spondin 1 protects against inflammatory bone damage during murine arthritis by modulating the Wnt pathway
    Gerhard Kronke
    University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 62:2303-12. 2010
    ..This study was undertaken to investigate the role of the Wnt pathway modulator R-Spondin 1 (RSpo1) in protecting bone and cartilage in a mouse model of arthritis...
  29. ncbi Vitamin D receptor regulates TNF-mediated arthritis
    Karin Zwerina
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 70:1122-9. 2011
    ..The pathophysiological role of vitamin D in joint inflammation is, however, unclear...
  30. ncbi The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis
    Katrin Palumbo
    Department of Internal Medicine, Institute for Clinical Immunology, University of Erlangen Nuremberg, Germany
    Ann Rheum Dis 70:1320-6. 2011
    ..Here, the role of JunD, a member of the activator protein 1 (AP-1) family of transcription factors, as a downstream mediator of TGF? signalling in systemic sclerosis (SSc), was investigated...
  31. ncbi The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss
    Christina Böhm
    Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    J Immunol 183:5938-47. 2009
    ..Thus, our data show that developing specific inhibitors of the alpha-isoenzyme of p38 would be beneficial for the treatment of inflammation-induced bone destruction as observed in rheumatoid arthritis...
  32. ncbi Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation
    Mario M Zaiss
    University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 62:2328-38. 2010
    ..The aim of this study was to determine whether immune regulatory mechanisms, such as naturally occurring Treg cells, also extend their protective effects to bone homeostasis in vivo...
  33. ncbi Microparticles stimulate angiogenesis by inducing ELR(+) CXC-chemokines in synovial fibroblasts
    Nicole Reich
    Department for Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    J Cell Mol Med 15:756-62. 2011
    ..Our data suggest that MPs may contribute to the hypervascularization of inflamed joints in patients with rheumatoid arthritis...
  34. ncbi Inhibition of glycogen synthase kinase 3? induces dermal fibrosis by activation of the canonical Wnt pathway
    Christina Bergmann
    Correspondence to Jörg H W Distler, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Germany
    Ann Rheum Dis 70:2191-8. 2011
    ..A study was undertaken to define the role of GSK-3 in fibroblast activation and in experimental models of systemic sclerosis (SSc)...
  35. ncbi Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts
    Alfiya Akhmetshina
    University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 58:2553-64. 2008
    ..Inhibitors of Rock are currently being evaluated for the treatment of pulmonary arterial hypertension. This study was undertaken to analyze the role of Rock in the activation of fibroblasts in systemic sclerosis (SSc)...
  36. ncbi Platelet-derived serotonin links vascular disease and tissue fibrosis
    Clara Dees
    Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen Nuremberg, 91054 Erlangen, Germany
    J Exp Med 208:961-72. 2011
    ..These findings suggest that 5-HT/5-HT(2B) signaling links vascular damage and platelet activation to tissue remodeling and identify 5-HT(2B) as a novel therapeutic target to treat fibrotic diseases...
  37. ncbi Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo
    Roland Axmann
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Krankenhausstrasse 12, Erlangen, Germany
    Arthritis Rheum 60:2747-56. 2009
    ..To investigate the efficacy of a murine anti-interleukin-6 receptor (anti-IL-6R) antibody in directly blocking tumor necrosis factor (TNF)- and RANKL-mediated osteoclastogenesis in vitro and in vivo...
  38. ncbi IgG opsonized nuclear remnants from dead cells cause systemic inflammation in SLE
    Luis E Munoz
    Department for Internal Medicine 3, University Hospital Erlangen, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Bavaria, 91054, Germany
    Autoimmunity 43:232-5. 2010
    ..In conclusion, the proinflammatory phagocytosis by circulating phagocytes of IgG-opsonized cellular remnants fosters systemic inflammation in SLE...
  39. ncbi Validation of a radiographic scoring system for haemochromatosis arthropathy
    Tomas Dallos
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 69:2145-51. 2010
    ..Although its radiographic features are well known, there is no assessment tool for their evaluation...
  40. ncbi Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis
    Gisela Ruiz-Heiland
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nurnberg, Erlangen, Germany
    Ann Rheum Dis 71:400-7. 2012
    ..Osteophyte formation is a common phenomenon in arthritis. Bone formation by endochondral ossification is considered a key pathophysiological process in the formation of osteophytes...
  41. ncbi Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis
    Sieglinde Marquart
    University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 62:3467-76. 2010
    ..The aim of the present study was to evaluate the role of CB1 in systemic sclerosis...
  42. ncbi The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis
    Alfiya Akhmetshina
    University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 60:1129-36. 2009
    ..The cannabinoid receptor CB2 is predominantly expressed in non-neuronal tissue and exerts potent immunomodulatory effects. This study was undertaken to evaluate the role of CB2 in the pathogenesis of dermal fibrosis...
  43. ncbi High frequency of autoantibody-secreting cells and long-lived plasma cells within inflamed kidneys of NZB/W F1 lupus mice
    Charlotte Starke
    Department of Internal Medicine 3, Clinical Research Group, Nikolaus Fiebiger Center of Molecular Medicine, University of Erlangen Nuremberg, Erlangen, Germany
    Eur J Immunol 41:2107-12. 2011
    ..Moreover, the frequencies of IgG-secreting cells specific for the autoantigens dsDNA and nucleolin were higher in the kidneys compared with those in the spleen and bone marrow...
  44. ncbi Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis
    Clara Dees
    University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 63:1396-404. 2011
    ..The present study was undertaken to investigate the role of Notch signaling in SSc and to evaluate the therapeutic potential of Notch inhibition for the treatment of fibrosis...
  45. ncbi Hereditary hemochromatosis as a risk factor for joint replacement surgery
    Enijad Sahinbegovic
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Erlangen, Germany
    Am J Med 123:659-62. 2010
    ..Hemochromatosis is an inherited disease with iron overload and joint involvement resembling osteoarthritis. To determine the rate of joint replacement surgery in patients with hemochromatosis, we performed a cross-sectional cohort study...
  46. ncbi Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression
    Gisela Ruiz Heiland
    Department of Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 69:2152-9. 2010
    ..It was hypothesised that impaired bone formation is a key component in inflammatory bone loss and that Dkk-1, a Wnt antagonist, is a strong inhibitor of osteoblast-mediated bone formation...
  47. ncbi Induction of apoptosis in circulating angiogenic cells by microparticles
    Jörg H W Distler
    University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 63:2067-77. 2011
    ..The aim of this study was to analyze whether microparticles might link pathologic activation and apoptosis of ECs with reduced numbers of CACs...
  48. ncbi Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis
    Sonja Herman
    Department of Internal Medicine III, Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 58:3041-50. 2008
    ..This study was undertaken to define the role of costimulation in osteoclast differentiation during inflammatory arthritis...
  49. ncbi Oxidation of the alarmin high-mobility group box 1 protein (HMGB1) during apoptosis
    Vilma Urbonaviciute
    IZKF, research group N2, Nikolaus Fiebiger Center of Molecular Medicine, University Hospital Erlangen, University of Erlangen Nuremberg, Erlangen, Germany
    Autoimmunity 42:305-7. 2009
    ..Also HMGB1 in plasma of patients with systemic lupus was reversibly oxidized. In conclusion, HMGB1 undergoes reversible oxidative modifications at cysteine residues during cell death, which may modulate its biological properties...
  50. ncbi Polymorphisms in the Hsp70 gene locus are genetically associated with systemic lupus erythematosus
    Barbara G Fürnrohr
    Nikolaus Fiebiger Centre of Molecular Medicine, University of Erlangen Nuremberg, Germany
    Ann Rheum Dis 69:1983-9. 2010
    ..Heat shock proteins (Hsps) play a role in the delivery and presentation of antigenic peptides and are thought to be involved in the pathogenesis of multifactorial diseases...
  51. ncbi The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib
    Veronika R Lang
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Erlangen, Germany
    J Immunol 185:5637-47. 2010
    ..In contrast, the early T-independent type 2 response protecting the organism against blood-borne pathogens remains largely intact due to a remarkable resistance of MZ B cells against proteasome inhibition...
  52. ncbi Activation of canonical Wnt signalling is required for TGF-?-mediated fibrosis
    Alfiya Akhmetshina
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, 91054 Erlangen, Germany
    Nat Commun 3:735. 2012
    ..These findings demonstrate that canonical Wnt signalling is necessary for TGF-?-mediated fibrosis and highlight a key role for the interaction of both pathways in the pathogenesis of fibrotic diseases...
  53. ncbi Synovial immunopathology in haemochromatosis arthropathy
    Gisela Ruiz Heiland
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Krankenhausstrasse 12, 91054 Erlangen, Germany
    Ann Rheum Dis 69:1214-9. 2010
    ..Hereditary haemochromatosis (HH) is a common autosomal recessive inherited disorder that frequently causes arthritis. The pathophysiology of musculoskeletal involvement is, however, unclear...
  54. ncbi 12/15-lipoxygenase counteracts inflammation and tissue damage in arthritis
    Gerhard Kronke
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Erlangen, Germany
    J Immunol 183:3383-9. 2009
    ..Taken together, these results support an anti-inflammatory and tissue-protective role of 12/15-LO and its products during chronic inflammatory disorders such as arthritis...
  55. ncbi Molecular mechanisms of inflammatory bone damage: emerging targets for therapy
    Sonja Herman
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Krankenhausstrasse 12, D 91054 Erlangen, Germany
    Trends Mol Med 14:245-53. 2008
    ....
  56. ncbi Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells
    Silke Meister
    IZKF N2, Nikolaus Fiebiger Center of Molecular Medicine, University of Erlangen Nuremberg, Erlangen, Germany
    Neoplasia 12:550-61. 2010
    ..Thus, the combination of bortezomib with verapamil may improve the efficacy of proteasome inhibitory therapy...
  57. ncbi The uptake by blood-borne phagocytes of monosodium urate is dependent on heat-labile serum factor(s) and divalent cations
    Christine Schorn
    Deparment for Internal Medicine 3, Friedrich Alexander University of Erlangen Nurnberg, Erlangen, Germany
    Autoimmunity 43:236-8. 2010
    ..The uptake induces the release of the pro-inflammatory cytokines IL-1beta/IL-18/TNFalpha and IL-6/IL-8 by monocytes and PMN, respectively...
  58. ncbi Decreased lymphatic vessel counts in patients with systemic sclerosis: association with fingertip ulcers
    Alfiya Akhmetshina
    University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 62:1513-22. 2010
    ..This study was undertaken to assess whether the lymphatic vascular system is affected in SSc, and whether changes to the lymphatic vessels are associated with dystrophic changes and tissue damage in patients with SSc...
  59. ncbi The 12/15-lipoxygenase pathway promotes osteoclast development and differentiation
    Gerhard Kronke
    Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen Nuremberg, 91054, Erlangen, Germany
    Autoimmunity 42:383-5. 2009
    ..Therefore, 12/15-LO and its human homologue 15-LO may display novel targets for the treatment of diseases such as osteoporosis and rheumatoid arthritis...
  60. ncbi Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis
    Catherine Skhirtladze
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 58:1475-84. 2008
    ..Src kinases are nonreceptor tyrosine kinases, which have been implicated in cytoskeletal organization and cell mobility. This study was undertaken to evaluate the potential of Src kinases as novel targets of antifibrotic therapies...
  61. ncbi Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis
    Alfiya Akhmetshina
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Universitätsstr 29, 91054 Erlangen, Germany
    FASEB J 22:2214-22. 2008
    ..Thus, we provide the first evidence that dasatinib and nilotinib might be promising drugs for the treatment of patients with SSc...
  62. ncbi Musculoskeletal disease burden of hereditary hemochromatosis
    Enijad Sahinbegovic
    University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 62:3792-8. 2010
    ..To determine the prevalence, clinical picture, and disease burden of arthritis in patients with hereditary hemochromatosis...
  63. ncbi Sodium overload and water influx activate the NALP3 inflammasome
    Christine Schorn
    Department of Internal Medicine 3, University of Erlangen Nuremberg, 91054 Erlangen, Germany
    J Biol Chem 286:35-41. 2011
    ..As a translational aspect one may consider the use of chloroquine for the anti-inflammatory treatment of refractory gout...
  64. ncbi Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis
    Karin Polzer
    University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 63:670-80. 2011
    ..Recently, bortezomib was shown to directly inhibit osteoclastogenesis. The aim of this study was to analyze the influence and therapeutic effect of bortezomib in a mouse model of inflammatory arthritis...
  65. ncbi Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis
    Nicole Reich
    Department for Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 71:737-45. 2012
    ..This study analysed the antifibrotic effects of the selective c-Jun N-terminal kinase (JNK) inhibitor, CC-930, which recently entered first clinical trials as a novel antifibrotic approach...
  66. ncbi Dickkopf-1 is a master regulator of joint remodeling
    Danielle Diarra
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nurnberg, Krankenhausstrasse 12, D 91054 Erlangen, Germany
    Nat Med 13:156-63. 2007
    ..We identified tumor necrosis factor-alpha (TNF) as a key inducer of DKK-1 in the mouse inflammatory arthritis model and in human rheumatoid arthritis. These results suggest that the Wnt pathway is a key regulator of joint remodeling...
  67. ncbi Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion
    Stephanie Finzel
    Department of Internal Medicine 3, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 70:1587-93. 2011
    ..To investigate whether bone erosions in patients with rheumatoid arthritis (RA) show evidence of repair...
  68. ncbi IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss
    Mario M Zaiss
    Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen Nuremberg, D 91054 Erlangen, Germany
    J Immunol 186:6097-105. 2011
    ..Thus, we show in this study that IL-33 is an important bone-protecting cytokine and may be of therapeutic benefit in treating bone resorption...
  69. ncbi Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis
    Jerome Avouac
    University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 63:800-9. 2011
    ..The aim of this study was to investigate the contribution of STAT-4 in the development of a fibrotic phenotype in 2 different mouse models of experimental dermal fibrosis...
  70. ncbi Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease
    Jörg H W Distler
    University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 58:2538-42. 2008
    ..These findings suggest that imatinib mesylate might be effective in patients with fibrotic diseases and warrant the initiation of larger clinical studies on the safety and efficacy of imatinib mesylate in connective tissue diseases...
  71. ncbi Pharmacotherapy: concepts of pathogenesis and emerging treatments. Novel targets in bone and cartilage
    Christian Beyer
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Krankenhausstrasse 12, 91054 Erlangen, Germany
    Best Pract Res Clin Rheumatol 24:489-96. 2010
    ..Future therapies will likely target the pathologic activity of these molecular pathways to specifically block either catabolic or anabolic joint remodelling in arthritis...
  72. ncbi Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography
    Christian M Stach
    University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 62:330-9. 2010
    ..To define the nature of structural bone changes in patients with rheumatoid arthritis (RA) compared with those in healthy individuals by using the novel technique of high-resolution microfocal computed tomography (micro-CT)...
  73. ncbi Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study
    Jochen Zwerina
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Krankenhausstrasse 12, 91054 Erlangen, Germany
    Rheumatology (Oxford) 50:1823-7. 2011
    ..To determine the potential of eotaxin-3 as a diagnostic marker for active disease and genetic susceptibility factor for Churg-Strauss syndrome (CSS)...
  74. ncbi Autoimmunity and chronic inflammation - two clearance-related steps in the etiopathogenesis of SLE
    Luis E Munoz
    Department for Internal Medicine 3, University Hospital Erlangen, Friedrich Alexander University of Erlangen Nuremberg, 91054 Erlangen, Germany
    Autoimmun Rev 10:38-42. 2010
    ..Chronic inflammation in SLE is consequently promoted by the persistently binding of AAb with their cognate autoantigens forming a binary weapon: the nucleic acid-containing IC...
  75. ncbi Treatment with DNAse I fosters binding to nec PBMC of CRP
    Christina Janko
    Department for Internal Medicine 3, Institute for Clinical Immunology, Friedrich Alexander University of Erlangen Nurnberg, Erlangen, Germany
    Autoimmunity 42:286-8. 2009
    ..Consequently, reduced DNase I activity in patients with SLE may contribute to the impaired opsonisation by CRP of dead cells, exacerbating the clearance defect in SLE of apo and nec cells...
  76. ncbi Sodium and potassium urate crystals differ in their inflammatory potential
    Christine Schorn
    Department for Internal Medicine 3, Institute for Clinical Immunology, Friedrich Alexander University of Erlangen Nurnberg, Erlangen, Germany
    Autoimmunity 42:314-6. 2009
    ..These results show that the cation of urate crystals determines the response of innate immune cells, indicating that the micromilieu at the site of crystal formation is important for their inflammatory potential...
  77. ncbi TNF and bone
    Jean Pierre David
    Rheumatology and Immunology, Department of Internal Medicine 3, University of Erlangen Nuremberg, Krankenhausstrasse 12, Erlangen, Germany
    Curr Dir Autoimmun 11:135-44. 2010
    ..The role of TNF-alpha in mediating bone remodeling will be presented and discussed in this chapter...
  78. ncbi A case report of plasma exchange, steroids, mycophenolate mofetil and cyclophosphamide in acquired factor VIII inhibitors
    Jürgen Rech
    Medical Department 3, Division of Rheumatology, University of Erlangen Nuremberg, Munich, Germany
    Ther Apher Dial 12:406-8. 2008
    ..Hence, we present a case of severe idiopathic FVIII inhibitor-positive hemophilia successfully treated with the combination of plasma exchange, corticosteroids, cyclophosphamide and MMF...
  79. ncbi CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome
    Tomas Dallos
    University of Erlangen Nuremberg, Erlangen, Germany Comenius University in Bratislava, Bratislava, Slovakia
    Arthritis Rheum 62:3496-503. 2010
    ..CCL17/thymus and activation-regulated chemokine (TARC) is a chemokine responsible for the recruitment of Th2 cells. This study was undertaken to explore a possible role of CCL17/TARC in CSS...
  80. ncbi The lonely death: chondrocyte apoptosis in TNF-induced arthritis
    Karin Polzer
    Department of Internal Medicine 3, Institute of Clinical Immunology, University of Erlangen, Erlangen, Germany
    Autoimmunity 40:333-6. 2007
    ..These data indicate that chondrocyte death may play a primary role in inflammatory arthritis fueling cartilage inflammation and damage due to secondary necrosis...
  81. ncbi Joint remodelling in inflammatory disease
    Georg Schett
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Krankenhausstrasse 12, D 91054 Erlangen, Germany
    Ann Rheum Dis 66:iii42-4. 2007
    ..Whereas a short and self-limited activation of the immune system has no clinically meaningful effect on bone, prolonged immune activation as found in chronic inflammatory disease inevitably leads to bone wasting...
  82. ncbi Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus
    Luis E Munoz
    University Hospital of Erlangen, Department of Radiation Oncology, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Rheum 60:1733-42. 2009
    ..The aim of this study was to investigate whether the remnants of apoptotic cells are involved in the induction of inflammatory cytokines in blood-borne phagocytes...
  83. ncbi Pathophysiology of spondyloarthritis
    Monika Ronneberger
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Ulmenweg 18, Erlangen 91054, Germany
    Curr Rheumatol Rep 13:416-20. 2011
    ..It also addresses the nature of inflammation in SpA and the mechanisms of ankylosis...
  84. ncbi Review: Immune cells and mediators of inflammatory arthritis
    Georg Schett
    Department of Internal Medicine 3, University of Erlangen Nurnberg, Erlangen, Germany
    Autoimmunity 41:224-9. 2008
    ..Inhibition of osteoclast formation has proven as an effective approach to inhibit structural damage in experimental arthritis and preliminary data suggest that such approaches are also effective in human RA...
  85. ncbi Pathogenesis of Churg-Strauss syndrome: recent insights
    Jochen Zwerina
    Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Autoimmunity 42:376-9. 2009
    ..This review summarizes recent advances in the knowledge on epidemiology, clinical features, and pathogenesis of CSS...
  86. ncbi Churg-Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patients
    Jochen Zwerina
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Semin Arthritis Rheum 39:108-15. 2009
    ..To describe the clinical characteristics of children with Churg-Strauss syndrome (CSS) in comparison with adult patients...
  87. ncbi MoMa from patients with systemic lupus erythematosus show altered adhesive activity
    Luis E Munoz
    Department for Internal Medicine 3, Institute for Clinical Immunology and Rheumatology, 91054, Erlangen, Germany
    Autoimmunity 42:269-71. 2009
    ..These findings suggest that there is an alteration in the integrin and/or FcgammaR mediated stimulation of MoMa from SLE patients and this alteration may be associated with the impaired clearance of apo cells seen in this disease...
  88. ncbi Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease
    Jörg H W Distler
    Department of Internal Medicine, Institute for Clinical Immunology, University of Erlangen Nuremberg, Germany
    Ann Rheum Dis 70:1197-202. 2011
    ..Vascular disease is common in mixed connective tissue disease (MCTD). The aim of the present study was to investigate, whether dysbalance of angiogenic and angiostatic factors occurs in MCTD...
  89. ncbi Remission of demyelinating polyneuropathy with immunoadsorption, low dose corticosteroids and anti-CD20 monoclonal antibody
    Jürgen Rech
    Medical Department III, University of Erlangen Nuremberg, Erlangen, Germany
    Ther Apher Dial 12:205-8. 2008
    ..Immunoadsorption in combination with a monoclonal anti-CD20 antibody in patients with demyelinating polyneuropathy with anti-MAG is effective and can be used an alternative treatment option in patients with progressive disease...
  90. ncbi Measuring joint involvement in polyarticular psoriatic arthritis: an introduction of alternatives
    M Englbrecht
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Care Res (Hoboken) 62:977-83. 2010
    ..To compare the reliability of 3 different simplified joint counts with the gold standard 66 swollen/68 tender joint count (JC66/68) for assessing clinical response in patients with polyarticular psoriatic arthritis (PsA)...
  91. ncbi Use of methotrexate in adult-onset Still's disease
    B Manger
    Medizinische Klinik 3, Friedrich Alexander Universitat Erlangen Nurnberg, Erlangen, Germany
    Clin Exp Rheumatol 28:S168-71. 2010
    ..If the response to this treatment is incomplete, additional therapies, such as biologic agents may be appropriate...
  92. ncbi Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis
    J H W Distler
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, G1054 Erlangen, Germany
    Rheumatology (Oxford) 48:98-103. 2009
    ..Antagonists against the receptor CCR2 are currently tested in clinical trials of a variety of diseases and also represent interesting candidates for target-directed therapy in SSc...
  93. ncbi [Mesenchymal stem cells in arthritis]
    J P David
    Medizinische Klinik 3, Rheumatologie und Immunologie, Universitatsklinikum Erlangen, Krankenhausstr 12, 91054, Erlangen, Deutschland
    Z Rheumatol 68:228-33. 2009
    ..This review focuses on the characterization and potential application of MSCs in the regeneration of damaged joints...
  94. ncbi Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE
    Vilma Urbonaviciute
    Interdisciplinary Center of Clinical Research IZKF, research group N2, Nikolaus Fiebiger Center of Molecular Medicine, University Hospital Erlangen, University of Erlangen Nuremberg, Erlangen, Germany
    J Exp Med 205:3007-18. 2008
    ..In conclusion, HMGB1-nucleosome complexes activate antigen presenting cells and, thereby, may crucially contribute to the pathogenesis of SLE via breaking the immunological tolerance against nucleosomes/dsDNA...
  95. ncbi Treg cells suppress osteoclast formation: a new link between the immune system and bone
    Mario M Zaiss
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Krankenhausstrasse 12, Erlangen, Germany
    Arthritis Rheum 56:4104-12. 2007
    ..To investigate whether Treg cells can suppress osteoclast differentiation, and to define a new potential link between the immune system and the skeleton...
  96. ncbi High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study
    Georg Schett
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Arch Intern Med 166:2495-501. 2006
    ..It is unknown, however, whether low-grade inflammation in healthy individuals, as estimated by the high-sensitivity C-reactive protein (hs-CRP) level, interferes with bone metabolism and affects the risk of nontraumatic fractures...
  97. ncbi From bone biology to clinical outcome: state of the art and future perspectives
    Georg Schett
    Department of Internal Medicine 3, Erlangen, Germany
    Ann Rheum Dis 69:1415-9. 2010
    ..In the last decade the well-known negative influences of glucocorticoids on bone have become more treatable as a result of new drugs that stimulate osteoblasts and restore the negative bone balance...
  98. ncbi Erosive arthritis
    Georg Schett
    Department of Internal Medicine 3, University of Erlangen Nurnberg, Erlangen, Germany
    Arthritis Res Ther 9:S2. 2007
    ..Blockade of osteoclast formation is thus a key strategy in preventing structural damage in arthritis. Denosumab, a humanized antibody that neutralizes RANKL, is an attractive candidate agent to inhibit inflammatory bone loss...
  99. ncbi Cells of the synovium in rheumatoid arthritis. Osteoclasts
    Georg Schett
    Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Arthritis Res Ther 9:203. 2007
    ..Osteoclasts thus represent a link between joint inflammation and structural damage since they resorb mineralized tissue adjacent to the joint and destroy the joint architecture...
  100. ncbi Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints
    K Polzer
    Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    Ann Rheum Dis 67:1610-6. 2008
    ..To investigate the presence and regulation of lymphatic vessels in inflamed joints of mice with experimental arthritis as well as patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA)...